Literature DB >> 10602522

Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.

W T Loging1, D Reisman.   

Abstract

The p53 gene is a tumor suppressor that regulates the expression of genes required for cell cycle arrest or apoptosis. Mutations in p53 have been observed in over 60% of all human cancers. Certain classes of mutant p53 proteins maintain some of their activities or acquire novel activities and thus may contribute to the transformed phenotype. By carrying out an analysis of differential gene expression using cDNA expression arrays, we compared the expression patterns of cells expressing no p53 to isogenic lines expressing the codon 248 Arg to Trp mutant p53 allele (R248W). In this report, we show that the R248W and D281G p53 mutants, two of the more commonly occurring mutations, as well as wild type p53, repress transcription of the tissue inhibitor of metalloproteinases type 3 (TIMP-3) gene by greater than tenfold. TIMP-3 expression has been observed to be repressed in many tumors and its reduced expression is thought to contribute to tumor metastasis and invasiveness by allowing increased activity of metalloproteinases in the extracellular matrix. Since mutant forms of p53 tend to be expressed at greatly elevated levels in many human tumors, the retention of their ability to repress TIMP-3 illustrate one mechanism by which mutant forms of the p53 gene may contribute to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602522     DOI: 10.1038/sj.onc.1203135

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression.

Authors:  Pauli Puolakkainen; Aino Koski; Sanna Vainionpää; Zhanlong Shen; Heikki Repo; Esko Kemppainen; Harri Mustonen; Hanna Seppänen
Journal:  Med Oncol       Date:  2014-02-14       Impact factor: 3.064

2.  Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.

Authors:  Renyuan Zhou; Reneé Shanas; Mark A Nelson; Achyut Bhattacharyya; Jiaqi Shi
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

3.  Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release.

Authors:  Damien Destouches; Eric Huet; Maha Sader; Sophie Frechault; Gilles Carpentier; Florie Ayoul; Jean-Paul Briand; Suzanne Menashi; José Courty
Journal:  J Biol Chem       Date:  2012-10-29       Impact factor: 5.157

4.  Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.

Authors:  Eleni Mylona; Christina Magkou; Ioanna Giannopoulou; George Agrogiannis; Sofia Markaki; Antonios Keramopoulos; Lydia Nakopoulou
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

5.  Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas.

Authors:  Li-Jun Xiao; Shuang Zhao; En-Hong Zhao; Xin Zheng; Wen-Feng Gou; Yasuo Takano; Hua-Chuan Zheng
Journal:  Oncol Lett       Date:  2013-08-19       Impact factor: 2.967

6.  [Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer].

Authors:  Hong Yang; Jie Li; Jia Guo; Shangfu Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-04

Review 7.  p53's Extended Reach: The Mutant p53 Secretome.

Authors:  Evangelos Pavlakis; Thorsten Stiewe
Journal:  Biomolecules       Date:  2020-02-15

Review 8.  Mutant p53 in cell-cell interactions.

Authors:  Steven Pilley; Tristan A Rodriguez; Karen H Vousden
Journal:  Genes Dev       Date:  2021-04-01       Impact factor: 11.361

9.  Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.

Authors:  Wai-Hang Leung; Queenie P Vong; Wenwei Lin; Laura Janke; Taosheng Chen; Wing Leung
Journal:  J Exp Med       Date:  2013-11-04       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.